thalidomide has been researched along with Cognitive Dysfunction in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Cognitive Dysfunction: Diminished or impaired mental and/or intellectual function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide is a widely prescribed immunomodulatory drug (iMiD) for multiple myeloma, but causes reversible memory loss in humans." | 5.48 | BK channel blocker paxilline attenuates thalidomide-caused synaptic and cognitive dysfunctions in mice. ( Choi, SY; Choi, TY; Jo, Y; Kim, SJ; Lee, SH; Park, CS, 2018) |
| "Thalidomide is a widely prescribed immunomodulatory drug (iMiD) for multiple myeloma, but causes reversible memory loss in humans." | 1.48 | BK channel blocker paxilline attenuates thalidomide-caused synaptic and cognitive dysfunctions in mice. ( Choi, SY; Choi, TY; Jo, Y; Kim, SJ; Lee, SH; Park, CS, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, TY | 1 |
| Lee, SH | 1 |
| Kim, SJ | 1 |
| Jo, Y | 1 |
| Park, CS | 1 |
| Choi, SY | 1 |
1 other study available for thalidomide and Cognitive Dysfunction
| Article | Year |
|---|---|
BK channel blocker paxilline attenuates thalidomide-caused synaptic and cognitive dysfunctions in mice.
Topics: Animals; Cognitive Dysfunction; Excitatory Postsynaptic Potentials; Hippocampus; Humans; Immunosuppr | 2018 |